SATT Paris-Saclay
SATT Paris-Saclay is a French government-backed technology transfer accelerator (SAS, founded 2014, Orsay) that funds, matures, and commercializes deeptech research from 19 Paris-Saclay institutions via licensing to industrial partners and creation of spin-off startups (43 to date).
- Company typePrivate
- Founded2014
- HeadquartersOrsay, France
- Headcount51–100
- GTM typeB2B
- OfferingServices
What SATT Paris-Saclay does
SATT Paris-Saclay is a French technology transfer accelerator (Société par Actions Simplifiée) founded in 2014 that serves as the official commercialization vehicle for the Paris-Saclay innovation cluster, one of Europe's most research-dense ecosystems encompassing 19 research institutions including Université Paris-Saclay, Gustave Roussy, Inserm, AgroParisTech, INRAE, and IP Paris. The company identifies early-stage deeptech research, funds and matures promising technologies using public capital from the French Government's Programme d'Investissements d'Avenir (PIA), manages a portfolio of 575 active patent titles, and transfers technologies to market via two channels: licensing to established industrial partners (pharma, agri-biosciences, energy, digital) and creation of spin-off startups. As of the most recent disclosed metrics, SATT has supported 609+ researchers and entrepreneurs, maintained 58 active technology projects, achieved a 70% transfer rate, and contributed to 43 startups that have collectively raised €230M since 2014.
The portfolio spans healthcare, agriculture, energy, digital, and materials science. Notable projects include FAUST (AI diagnostic for hyperacute ischemic stroke MRI), PTPs-VAC (proteogenomic platform for personalized cancer vaccines, spun out as Kahimmune Therapeutics in November 2025), NOVATREAT (postbiotic/paraprobiotic supplements for type 2 diabetes prevention, commercialized as Orasuna/Ora1 in January 2026), Willis AI (Software-as-a-Medical-Device for automated brain MRI, launched 2025), AIRPAD (ventilator-patient synchronization), DIONYSOS (biocontrol for viticulture), CTAF (modular electric powertrain), and GASPARD (photoacoustic gas monitoring). Revenue mechanics combine technology licensing royalties, equity stakes taken in spin-off startups (e.g., €1M into Kimialys in 2023, €500K into ALSYMO in March 2023), and fee-based professional services including innovation strategy consulting, technology valuations, and market studies. The organization is headquartered in Orsay, France, employs 51-100 staff, and operates under a government mandate rather than as a market-driven venture capital entity.
SATT Paris-Saclay firmographics
Firmographics- Name
- SATT Paris-Saclay
- Legal name
- SATT Paris-Saclay, Société par Actions Simplifiée (SAS)
- Website
- https://satt-paris-saclay.fr
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- SATT Paris-Saclay is a French government-backed technology transfer accelerator (SAS, founded 2014, Orsay) that funds, matures, and commercializes deeptech research from 19 Paris-Saclay institutions via licensing to industrial partners and creation of spin-off startups (43 to date).
- Ownership category
- akta.pro rank
SATT Paris-Saclay industry classification
Industry- Product category
- Technology Transfer Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Patent Owners & Lessors (6794)
- akta.pro primary industry
- Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)
- akta.pro secondary industry
- Accelerator / Incubator-Backed ETA Programs (FSANALAD)
Keywords
Where SATT Paris-Saclay is headquartered
LocationHeadquarters
- HQ city
- Orsay
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
SATT Paris-Saclay business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology Licensing: SATT Paris-Saclay licenses technologies developed from public research to industrial partners, generating revenue through licensing fees and royalties.
- Start-up Equity Investment: SATT invests in and supports the creation of deeptech spin-off startups from the Paris-Saclay ecosystem. The organization takes equity stakes in these startups as part of its technology transfer model.
- Business Services: SATT Paris-Saclay provides innovation strategy services, technology valuation studies, market studies, and business services to companies seeking to connect with academic research from the Paris-Saclay cluster.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
SATT Paris-Saclay product offering
Product offeringCore offering
SATT Paris-Saclay is a technology transfer accelerator that invests in disruptive technologies emerging from 19 research institutions in the Paris-Saclay cluster, supports researchers in commercializing their inventions through technology maturation funding and intellectual property management, licenses the resulting innovations to industrial partners, and creates deeptech spin-off startups. The organization monetizes its portfolio of 575 active patents across healthcare, agriculture, energy, digital, and materials science via licensing royalties, equity stakes in spin-offs, and innovation consulting services.
Product overview
SATT Paris-Saclay operates as a technology transfer accelerator (Start-up Factory) supporting deeptech innovations from Paris-Saclay research institutions. The portfolio includes multiple technology projects across healthcare, agriculture, and mobility sectors. Key technologies include FAUST (AI-powered stroke diagnosis software), PTPs-VAC (cancer vaccine platform), NOVATREAT (diabetes prevention supplements), and Kahinomics platform (neoantigen discovery). These projects are developed into spin-off startups including Willis (W-Stroke for stroke MRI analysis), Kahimmune Therapeutics (mRNA cancer therapies), and Orasuna (Ora1 metabolic regulation). Additional technologies in development include AIRPAD (ventilator synchronization), DIONYSOS (biocontrol for viticulture), CTAF (electric powertrain), and GASPARD (gas monitoring).
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 43 deeptech startups founded and actively developing innovations on the market
- +4 more outcomes
Companies that use SATT Paris-Saclay
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
SATT Paris-Saclay technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
SATT Paris-Saclay partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- General InceptioncoreStrategic partnership with General Inception aimed at creating deeptech startups with world-renowned research laboratories, leveraging the combined expertise in technology transfer and startup development.
- IP Paris (Institut Polytechnique de Paris)minorPartnership between IP Paris and SATT Paris-Saclay to valorize technologies from the CIEDS (Centre Interdisciplinaire de Recherche en Stratégie) for industrial transfer and dual valorization.
- VitaDX / XPath GroupminorVitaDX announced collaboration with XPath Group for the continued deployment in France of its VisioCyt® solution for early bladder cancer diagnosis, with SATT Paris-Saclay having supported VitaDX's technology transfer.
- Technoriat / OurDigitalFutureminorPartnership between SATT Paris-Saclay and Technoriat to boost entrepreneurship and innovation in Tunisia, with OurDigitalFuture supporting the accompaniment of Tunisian researchers in their innovation projects.
- EPA Paris-Saclay (Établissement Public d'Aménagement)minorEPA Paris-Saclay partnered with SATT to create the first mutualized technological Showroom of Paris-Saclay, an exhibition space showcasing deeptech innovations and startups from the ecosystem.
- Biogen / TheraPanaceaminorTheraPanacea, a startup supported by SATT Paris-Saclay, entered into a collaboration with Biogen focused on neurosciences therapeutic areas, building on its AI-powered medical software platform.
- Valent BioSciencescoreSATT Paris-Saclay and Valent BioSciences signed a joint agreement to develop breakthrough sustainable biopesticide technologies, combining SATT's research access with Valent BioSciences' commercial expertise in biosciences.
- Servier GroupcoreServier Group and the SATT Network (including SATT Paris-Saclay) signed a partnership to identify innovative therapeutic projects, with SATT Paris-Saclay serving as an active node in the national network.
- Gustave RoussycoreGustave Roussy, France's leading cancer research center, partnered with SATT Paris-Saclay to develop the PTPs-VAC project for personalized anti-cancer vaccines using unconventional neoepitopes. This partnership resulted in the spin-off creation of Kahimmune Therapeutics in late 2025.
- AgroParisTechcoreAgroParisTech collaborated with SATT Paris-Saclay on the NOVATREAT project to develop food supplements for the prevention of type 2 diabetes based on postbiotic and paraprobiotic ingredients.
- INRAEcoreINRAE (Institut national de recherche pour l'agriculture, l'alimentation et l'environnement) partnered with SATT Paris-Saclay on the NOVATREAT project for developing food supplement technology targeting prediabetes.
- Université Paris-SaclaycoreUniversité Paris-Saclay is the primary academic partner of SATT Paris-Saclay, with the university reinforcing its confidence in SATT through ongoing conventions and the PUI (Pôle Universitaire d'Innovation) structure.
- InsermcoreInserm (Institut national de la santé et de la recherche médicale) is a key research institution partner in the PTPs-VAC project alongside Gustave Roussy and SATT Paris-Saclay for cancer vaccine development.
- French TechcorePartnership with the French Tech initiative including the French Tech Seed Paris-Saclay label, enabling startups from the ecosystem to access French Tech funding and support programs.
- SATT Network (Réseau des SATT)coreSATT Paris-Saclay participates in the national SATT Network, a consortium of technology transfer companies across France, enabling coordinated technology transfer and shared best practices.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
SATT Paris-Saclay competitors and assessment
Company assessmentDirect peers
- SATT Sud Est: Direct sister-SATT in France covering the PACA/Corse research cluster, operating the same PIA-funded technology-transfer-and-maturation model with licensing and startup equity creation, making it the closest functional peer for benchmarking operating model.
- SATT Conectus Alsace: Direct sister-SATT in the Alsace region of France, performing the same PIA-mandated tech-transfer, maturation funding, and startup creation from public research, comparable in size and scope to SATT Paris-Saclay.
- SATT Nord: French SATT serving the Hauts-de-France research base, competing and partnering within the national SATT Network on technology transfer, IP management, and deeptech spin-off creation—highly comparable in business model.
- INRIA Transfert: French national institute TTO (INRIA), also part of the national tech-transfer ecosystem, focused on digital and applied-math research with licensing and startup creation—overlaps directly with SATT Paris-Saclay's digital and AI verticals.
- CEA Valorisation: The French Alternative Energies and Atomic Energy Commission's tech-transfer arm, performing maturation, licensing, and spin-off creation from public research, directly comparable in institutional mission and revenue model to SATT Paris-Saclay.
Broad incumbents
- Oxford University Innovation: Mature university TTO at the University of Oxford doing technology licensing, equity in spin-offs, and consulting services from world-leading research; a broad incumbent comparable to SATT Paris-Saclay as a reference scale and operating model.
- Cambridge Enterprise: University of Cambridge's technology transfer and commercialization arm, providing IP management, licensing, and seed investment from a top global research base—structurally the same TTO business model as SATT Paris-Saclay, just at larger scale and older vintage.
- Max Planck Innovation: Technology transfer office of the Max Planck Society in Germany, licensing life-science and physical-science IP and supporting spin-offs—comparable in scope to SATT Paris-Saclay across health, digital, and energy verticals at European scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
SATT Paris-Saclay social profiles
Digital presenceSATT Paris-Saclay compliance and trust
Trust signalCompliance2 records
SATT Paris-Saclay financial estimates
Financial estimateRevenue estimate
Valuation estimate
SATT Paris-Saclay leadership team
Management profileNumber of profiles
Profiles1 record
SATT Paris-Saclay funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SATT Paris-Saclay M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SATT Paris-Saclay
What does SATT Paris-Saclay do?
SATT Paris-Saclay is a technology transfer accelerator that invests in disruptive technologies emerging from 19 research institutions in the Paris-Saclay cluster, supports researchers in commercializing their inventions through technology maturation funding and intellectual property management, licenses the resulting innovations to industrial partners, and creates deeptech spin-off startups. The organization monetizes its portfolio of 575 active patents across healthcare, agriculture, energy, digital, and materials science via licensing royalties, equity stakes in spin-offs, and innovation consulting services.
Is SATT Paris-Saclay a public or private company?
SATT Paris-Saclay is a private company. It is classified as state government owned and is currently operating.
When was SATT Paris-Saclay founded?
SATT Paris-Saclay was founded in 2014. It employs 51 to 100 people.
Where is SATT Paris-Saclay based?
SATT Paris-Saclay is headquartered in Orsay, France, in the Europe region.
How does SATT Paris-Saclay make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are start-up Equity Investment and business Services.
Who are SATT Paris-Saclay's main competitors?
Direct peers on record are SATT Sud Est, SATT Conectus Alsace, SATT Nord, INRIA Transfert and CEA Valorisation. Broad incumbents are Oxford University Innovation, Cambridge Enterprise and Max Planck Innovation.
Does SATT Paris-Saclay have an API?
No public API is recorded for SATT Paris-Saclay.
What industry is SATT Paris-Saclay in?
SATT Paris-Saclay's product category is Technology Transfer Services. Its primary akta.pro industry code is EDAHABAH, Technology Transfer & Innovation-Driven Research Universities (High Commercialization), with a secondary code of FSANALAD, Accelerator / Incubator-Backed ETA Programs. Its NAICS code is 5417 and its SIC code is 6794.